PubMed Health⌕ Search

Biomedical subjects

H Stickl

Publications and source records attributed to H Stickl.

At least 19 recordsLinked to original sources
PubMed1992

Hepatitis A vaccination: schedule for accelerated immunization.

Hepatitis A vaccine, strain HM175, was investigated for immunogenicity and tolerability in a prospective multicentre trial. The following vaccination schedules and antigen contents were evaluated: days 0 and 14 with 720 ELISA units (El.U) of antigen, days 0 and 28 with 720 El.U and days 0 and 28 with 360 El.U. In all study groups, the seroconversion rates following two vaccinations were between 95 and 100%. Higher geometric mean concentrations of antibody to hepatitis A virus (anti-HAV) were reached by the vaccine containing 720 El.U of HAV antigen. The vaccine was equally well tolerated in all groups. In addition, an abbreviated schedule, in which 720 El.U of HAV antigen was given on days 0 and 14, resulted in 100% seroconversion by day 28 and a level of anti-HAV that was substantially higher than that observed after passive immunization. This implies that such a vaccine could replace immune globulin administration if time permits.

Adult↗
PubMed1992

Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.

To study the immunogenicity and reactogenicity of an inactivated hepatitis A vaccine, 204 healthy individuals were randomized into three equal groups, each to receive a different vaccine lot. Each subject received a total of three doses, each of 720 ELISA units of hepatitis A vaccine HM175, according to a 0 and 1 month primary vaccination schedule, with a booster dose given at month 6. Side effects were low and were < 30% after the second injection. All subjects but one had antibodies to hepatitis A virus two months after the first dose of vaccine. At month 6 all vaccinees had seroconverted. There were no differences between the three vaccine lots with respect to side effects, seroconversion rates and geometric mean titre of antibodies. We conclude that the three lots of inactivated hepatitis A vaccine are safe, well tolerated and equally immunogenic.

Adult↗
PubMed1979

[Effectiveness of a new "paramunity" inducer (PIND-AVI) for human beings and animals].

Attenuated and by treatment with gamma rays inactivated avian Pox viruses (PIND-AVI) stimulate in man and animals selectively the T-lymphocytes. In this way PIND-AVI helps to repair a reduced reactivity of lymphocytes damaged by cytostatic chemotherapy: The lymphocyte stimulation by phytohemagglutinin could be normalized. In immunodeficient patients PIND-AVI showed very good effects in the treatment of herpes Virus infections.

Adjuvants, Immunologic↗
PubMed1979

[3 vaccines against influenza--which to choose].

Three types of a killed influenza vaccine are available in the Federal Republic of Germany: Whole-virus-vaccine, split-vaccine, subunit-vaccine. It is not only necessary to enforce the vaccination against influenza virus infection, but additionally to differentiate between the different types of vaccine in vaccinating children and adults with special risks.

Adult↗
PubMed1978

[Will Salk's polio vaccination be used again?].

The value and special problems of application of killed and life polio vaccines are compared and discussed. The vaccination with life polio vaccine will be continued generally. Killed polio vaccine may be useful in children with immunodeficiency only.

Antibody Formation↗
PubMed1978

[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

The MVA virus is a lab virus ideally suited for vaccination of both man and animal which can be differentiated from the known Vaccinia strains by the use of numerous biological markers. Its reduced virulence for the chick embryo, for experimental animals and for man is a particularly characteristic feature. With the exception of chick embryo fibroblasts, the MVA virus grows in cell cultures only abortively. This applies particularly to cells of human origin in which the cytopathic effect and plaque formation are completely missing. The restriction analysis of the DNS of the MVA virus demonstrates that its genetic structure differs from that of the CVA basic virus and other orthopox viruses. In contrast to the WHO reference strain Elstree, the MVA virus has a genome shortened by about 9 per cent. The use of the MVA virus for human vaccination is particularly indicated in persons to be vaccinated for the first time and likely to entail a risk (on account of allergies etc.) because it brings about a state of revaccination without complications. The MVA virus can be administered in intracutaneous, subcutaneous or intramuscular injections. Innocuoursness and successful vaccination have been demonstrated in more than 120000 persons. While other Vaccinia strains, such as the Elstree virus, experience a drastic increase of virulence in the immunosuppressed organism (subjected to whole-body irradiation), the MVA virus cannot be activated not even in this situation.

Animals↗
PubMed1977

[Pathogenesis of multiple sclerosis. Antibody dependent cytotoxicity of lymphocytes against myelin basic proteins in multiple sclerosis].

In 79 of 100 patients with multiple sclerosis, serum antibodies of the IgG type were demonstrated which render normal lymphocytes cytotoxic against basic protein of myelin. In 11 cerebrospinal fluids which were tested the antibody was also found. The method used was the release of 51Cr from chicken erythrocytes coated with antigen. The antibody-dependent lymphocyte cytotoxicity is related to the degree of activity of the disease and not to the evolution of the disease or its course. As the disease worsens, the frequency of positive reactions is higher than in inactive stages. The immunological reaction is very specific for multiple sclerosis, in patients with other neurological disorders only 5% had positive findings. The antibody-dependent cytotoxicity of lymphocytes against basic protein of myelin may be attributed with a certain diagnostic significance. The reaction seems suitable for the supervision of the course of multiple sclerosis and to check the effect of therapeutic measures. The antibody-dependent lymphocyte cytotoxicity against basic protein of myelin is considered to be significant in the pathogenesis of multiple sclerosis.

Antibody-Dependent Cell Cytotoxicity↗
PubMed1977

[Therapy of herpes zoster through active premunization. 2. Treatment of zoster patients, results of experimental and clinical studies, treatment results].

A brief review of the previous and generally inadequate methods for the treatment of Herpes Zoster is presented. The concept of "active premunization" by appropriate inducer to provide an objective treatment is defined. A "Premunization Inducer" (PIND) based on a particular non-infectious preparation of an avian pox ("avipox") virus has been shown to enhance non-specific defence mechanisms in the host by T-cell stimulation and to inhibit virus proliferation by the induction of Interferon. The mode of action, efficacy against different viruses and the safety of the preparation is described and discussed. 114 patients with Herpes Zoster were treated with this "premunization Inducer" either orally (for buccal absorption) or by means of a nasal spray. There were no side effects and in all cases there was a marked reduction in the duration of the illness up to the shedding of the last scab (about 15 days instead of the more usual 31 days). Pain was relieved in some cases within 6 hours and in the remainder within 2 days: a rapid resolution of the inflammation could be observed. There were practically no signs of postherpetic neurological complications among the patients treated (the usual incidence of post-herpetic neuritis is around 18%). The treatment of Herpes I and Herpes II infection other viral conditions will be reported elsewhere.

Adult↗
PubMed1977

[The development of vaccination as demonstrated on the development of the Bavarian State Vaccination Institute in the 19th and 20th centuries].

In 1801 the smallpox vaccination has been introduced in Bavaria by order of the Duke Franz Joseph. He appointed a Medical Superintendent, responsible for smallpox vaccinations for the whole country. This was the hour of birth for the Institute, too. The Institute developed quickly to a point of crystallization in the field of prophylactic medicine, research on infectious diseases and social pediatrics. By this Institute the "Retrovaccine" against smallpox was introduced 1856. 1967 -- 1976 an attenuated life smallpox-vaccine (MVA) has been developed. Some years ago the activities of the Institute had been focussed into research of complications after vaccinations and up to date, on the pathogenesis of Multiple Sclerosis. A historical review demonstrates the development of the Institute in the past up to modern activities in research, teaching students and postgraduate education and in medical practice.

Academies and Institutes↗